Coronavirus disease 2019 (COVID-19) monoclonal antibody treatments
covers a COVID-19 monoclonal antibody treatment, if all of these apply:
- You tested positive for COVID-19.
- You have a mild to moderate case of COVID-19.
- You’re at high risk of progressing to a severe case of COVID-19 and/or at high risk of requiring hospitalization.
You pay nothing for this treatment during the COVID-19 Public Health Emergency when you get the treatment from a Medicare provider or supplier.
This FDA-authorized treatment involves an infusion of monoclonal antibodies (specifically bamlanivimab, or casirivimab and imdevimab) to treat COVID-19. Health care providers can only administer the infusions consistent with the FDA’s requirements in specific facilities.